Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Eradication therapies for HIV Infection: time to begin again.

Margolis DM.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):347-53. doi: 10.1089/aid.2011.0017. Epub 2011 Mar 11. Review.

2.

Prospects for treatment of latent HIV.

Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM.

Clin Pharmacol Ther. 2013 Jan;93(1):46-56. doi: 10.1038/clpt.2012.202. Epub 2012 Oct 10. Review. Erratum in: Clin Pharmacol Ther. 2013 Apr;93(4):366.

3.

Therapy for persistent HIV.

Keedy KS, Margolis DM.

Trends Pharmacol Sci. 2010 May;31(5):206-11. doi: 10.1016/j.tips.2010.02.001. Epub 2010 Mar 5. Review.

4.

Finding a cure for HIV: will it ever be achievable?

Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N.

J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.

5.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
6.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
7.

Timely HAART initiation may pave the way for a better viral control.

Paci P, Martini F, Bernaschi M, D'Offizi G, Castiglione F.

BMC Infect Dis. 2011 Mar 1;11:56. doi: 10.1186/1471-2334-11-56.

8.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
9.

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.

Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005482. Review.

PMID:
16235406
10.

Attacking HIV provirus: therapeutic strategies to disrupt persistent infection.

Margolis DM, Archin NM.

Infect Disord Drug Targets. 2006 Dec;6(4):369-76. Review.

PMID:
17168802
11.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
12.

Influence of antiretroviral therapy on liver disease.

Kovari H, Weber R.

Curr Opin HIV AIDS. 2011 Jul;6(4):272-7. doi: 10.1097/COH.0b013e3283473405. Review.

PMID:
21508839
13.

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, Thawornwan U, Suntisuklappon B, Nilkamhang S, Sungkanuparph S; TIME Study Team.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):377-83. doi: 10.1097/QAI.0b013e31825b5e06.

PMID:
22592586
14.

Benefits from early treatment of HIV-1 infection.

Klein D.

Trends Mol Med. 2001 Jan;7(1):9. No abstract available.

PMID:
11427995
15.

Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.

Saksena NK, Potter SJ.

AIDS Rev. 2003 Jan-Mar;5(1):3-18. Review.

PMID:
12875103
16.

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.

Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Review.

PMID:
20238364
17.

Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children.

Cohen NJ, Oram R, Elsen C, Englund JA.

Pediatr Infect Dis J. 2002 Jul;21(7):647-53.

PMID:
12237597
18.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
19.

Immunomodulants for the treatment of HIV infection: the search goes on.

Clerici M.

Expert Opin Investig Drugs. 2006 Mar;15(3):197-200. Review.

PMID:
16503756
20.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

Supplemental Content

Support Center